Back to Press ReleaseSirnaomics Publishes Results Showing Dual Targeting Effects
2017.10.06
-
About Us
-
Science & Pipeline
-
Investor Relations
-
Partnership
-
News
-
Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Sirnaomics In The News
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- news
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Sirnaomics Ltd. Listed on Main Board of HKEX
- Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
- Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
- Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
- RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
- Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
- Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
- Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022
- Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
- Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
- Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
- Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
- Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
- Sirnaomics Develops Peptide Docking Vehicle (PDoV™) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
- Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
- Sirnaomics becoming a Constituent of Hang Seng Family of Indexes
- Sirnaomics' 2022 interim results presentation will be held on 31 August 2022
- Sirnaomics Advances GalAhead™-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
- Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
-
Sirnaomics in the News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
- Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
- Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement-Related Diseases
- Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year
- Media Outreach
-
-
Careers
-
About Us
-
Science & Pipeline
-
Investor Relations
-
Partnership
-
News
-
Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Sirnaomics In The News
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- news
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Press Release
- Sirnaomics Ltd. Listed on Main Board of HKEX
- Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
- Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
- Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
- RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
- Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
- Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
- Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022
- Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
- Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
- Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
- Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
- Sirnaomics Receives IND Clearance from the Taiwan Ministry of Health and Welfare for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment
- Sirnaomics Develops Peptide Docking Vehicle (PDoV™) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
- Sirnaomics Doses the First Patient in Phase I/II Clinical Study of RNAi Therapeutic STP705 for Treatment of Facial Squamous Cell Skin Cancer In Situ
- Sirnaomics becoming a Constituent of Hang Seng Family of Indexes
- Sirnaomics' 2022 interim results presentation will be held on 31 August 2022
- Sirnaomics Advances GalAhead™-Based RNAi Therapeutics for Treatment of Complement-Related Diseases
- Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
-
Sirnaomics in the News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- Sirnaomics In The News
- After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
- Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
- Sirnaomics Advances GalAhead-Based Drug Candidates Focused on Complement-Related Diseases
- Sirnaomics Testing STP144G Therapy With Eye Toward Human Trials Next Year
- Media Outreach
-
-
Careers
Previous
